Meeting
2016 ASCO Annual Meeting
Pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma.
Authors
Donald M. O'Rourke
University of Pennsylvania, Philadelphia, PA
Donald M. O'Rourke , MacLean Nasrallah , Jennifer J. Morrissette , Jan J. Melenhorst , Simon F. Lacey , Keith Mansfield , Maria Martinez-Lage , Arati Suvas Desai , Steven Brem , Eileen Maloney , Suyash Mohan , Sumei Wang , Gaurav Verma , Jean-Marc Navenot , Angela Shen , Zhaohui Zheng , Bruce Levine , Hideho Okada , Carl H. June , Marcela Valderrama Maus
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT02209376
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2067)
DOI
10.1200/JCO.2016.34.15_suppl.2067
Abstract #
2067
Poster Bd #
254
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1b multicenter study to evaluate CHM 1101 in patients with recurrent or progressive glioblastoma.
First Author: Jason Blair Litten
Poster
2021 ASCO Annual Meeting
A phase 1 study to evaluate chimeric antigen receptor (CAR) T cells incorporating a chlorotoxin tumor-targeting domain for patients with MMP2+ Recurrent or progressive glioblastoma (NCT04214392).
First Author: Behnam Badie
Poster
2019 ASCO Annual Meeting
Novel anti-EGFRvIII bispecific T cell engager (BiTE) antibody construct in glioblastoma (GBM): Trial in progress of AMG 596 in patients with recurrent or newly diagnosed disease.
First Author: Mark Rosenthal
First Author: Hong-jiu Dai